1. Mendiratta G, Ke E, Aziz M, Liarakos D, Tong M, Stites EC. Cancer gene mutation frequencies for the U.S. population. Nature Communications 2021 12:1 [Internet]. Nature Publishing Group; 2021 [cited 2023 Dec 11];12:1–11. Available from: https://www.nature.com/articles/s41467-021-26213-y
2. Oliveira C, Velho S, Moutinho C, Ferreira A, Preto A, Domingo E, et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 2007 26:1 [Internet]. Nature Publishing Group; 2006 [cited 2023 Nov 29];26:158–63. Available from: https://www.nature.com/articles/1209758
3. Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduction and Targeted Therapy 2021 6:1 [Internet]. Nature Publishing Group; 2021 [cited 2023 Nov 29];6:1–20. Available from: https://www.nature.com/articles/s41392-021-00780-4
4. Velho S, Moutinho C, Cirnes L, Albuquerque C, Hamelin R, Schmitt F, et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer [Internet]. BMC; 2008 [cited 2023 Nov 29];8:255. Available from: /pmc/articles/PMC2553419/
5. Velho S, Haigis KM. Regulation of homeostasis and oncogenesis in the intestinal epithelium by Ras. Exp Cell Res [Internet]. NIH Public Access; 2011 [cited 2023 Nov 29];317:2732. Available from: /pmc/articles/PMC3192920/
6. Boutin AT, Liao WT, Wang M, Hwang SS, Karpinets T V., Cheung H, et al. Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev [Internet]. Cold Spring Harbor Laboratory Press; 2017 [cited 2023 Nov 29];31:370–82. Available from: /pmc/articles/PMC5358757/
7. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nature Reviews Cancer 2011 11:11 [Internet]. Nature Publishing Group; 2011 [cited 2023 Nov 29];11:761–74. Available from: https://www.nature.com/articles/nrc3106
8. Dias Carvalho P, Martins F, Mendonça S, Ribeiro A, Machado AL, Carvalho J, et al. Mutant KRAS modulates colorectal cancer cells invasive response to fibroblast-secreted factors through the HGF/C-MET axis. Int J Cancer [Internet]. Int J Cancer; 2022 [cited 2023 Nov 29];151:1810–23. Available from: https://pubmed.ncbi.nlm.nih.gov/35869872/
9. Charitou T, Srihari S, Lynn MA, Jarboui MA, Fasterius E, Moldovan M, et al. Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRASG13D mutation. Br J Cancer [Internet]. Br J Cancer; 2019 [cited 2023 Nov 29];121:37–50. Available from: https://pubmed.ncbi.nlm.nih.gov/31133691/
10. Zocche DM, Ramirez C, Fontao FM, Costa LD, Redal MA. Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer. Front Genet [Internet]. Frontiers Media SA; 2015 [cited 2023 Nov 29];6. Available from: /pmc/articles/PMC4378307/
11. Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, et al. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev [Internet]. Cancer Treat Rev; 2010 [cited 2023 Nov 29];36 Suppl 3. Available from: https://pubmed.ncbi.nlm.nih.gov/21129611/
12. Hamarsheh S, Groß O, Brummer T, Zeiser R. Immune modulatory effects of oncogenic KRAS in cancer. Nature Communications 2020 11:1 [Internet]. Nature Publishing Group; 2020 [cited 2023 Nov 29];11:1–11. Available from: https://www.nature.com/articles/s41467-020-19288-6
13. Carvalho PD, Machado AL, Martins F, Seruca R, Velho S. Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors. Cancers (Basel) [Internet]. Cancers (Basel); 2019 [cited 2023 Nov 29];11. Available from: https://pubmed.ncbi.nlm.nih.gov/31847096/
14. Carvalho PD, Guimarães CF, Cardoso AP, Mendonça S, Costa ÂM, Oliveira MJ, et al. KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment. Cancer Res [Internet]. Cancer Res; 2018 [cited 2023 Nov 29];78:7–14. Available from: https://pubmed.ncbi.nlm.nih.gov/29263151/
15. Merz V, Gaule M, Zecchetto C, Cavaliere A, Casalino S, Pesoni C, et al. Targeting KRAS: The Elephant in the Room of Epithelial Cancers. Front Oncol [Internet]. Front Oncol; 2021 [cited 2023 Nov 29];11. Available from: https://pubmed.ncbi.nlm.nih.gov/33777798/
16. Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med [Internet]. N Engl J Med; 2020 [cited 2023 Nov 29];383:1207–17. Available from: https://pubmed.ncbi.nlm.nih.gov/32955176/
17. Kim D, Herdeis L, Rudolph D, Zhao Y, Böttcher J, Vides A, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature 2023 619:7968 [Internet]. Nature Publishing Group; 2023 [cited 2023 Nov 29];619:160–6. Available from: https://www.nature.com/articles/s41586-023-06123-3
18. Nichols RJ, Yang YC, Cregg J, Schulze CJ, Wang Z, Dua R, et al. Abstract 3595: RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers. Cancer Res [Internet]. American Association for Cancer Research; 2022 [cited 2023 Nov 29];82:3595–3595. Available from: https://dx.doi.org/10.1158/1538-7445.AM2022-3595
19. Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nature Medicine 2022 28:10 [Internet]. Nature Publishing Group; 2022 [cited 2023 Nov 29];28:2171–82. Available from: https://www.nature.com/articles/s41591-022-02007-7
20. Koltun E, Cregg J, Rice MA, Whalen DM, Freilich R, Jiang J, et al. Abstract 1260: First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers. Cancer Res [Internet]. American Association for Cancer Research; 2021 [cited 2023 Nov 29];81:1260–1260. Available from: https://dx.doi.org/10.1158/1538-7445.AM2021-1260
21. Hallin J, Engstrom LD, Hargi L, Calinisan A, Aranda R, Briere DM, et al. The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. Cancer Discov [Internet]. NIH Public Access; 2020 [cited 2023 Nov 29];10:54. Available from: /pmc/articles/PMC6954325/
22. Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol [Internet]. Elsevier Ltd; 2022 [cited 2023 Nov 29];23:115–24. Available from: http://www.thelancet.com/article/S1470204521006057/fulltext
23. Bekaii-Saab TS, Yaeger R, Spira AI, Pelster MS, Sabari JK, Hafez N, et al. Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation. J Clin Oncol [Internet]. J Clin Oncol; 2023 [cited 2023 Nov 29];41:4097–106. Available from: https://pubmed.ncbi.nlm.nih.gov/37099736/
24. Johnson ML, Ou SHI, Barve M, Rybkin II, Papadopoulos KP, Leal TA, et al. KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation. Eur J Cancer [Internet]. Elsevier BV; 2020 [cited 2023 Nov 29];138:S2. Available from: http://www.ejcancer.com/article/S0959804920310777/fulltext
25. De Conti G, Dias MH, Bernards R. Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells. Cancers (Basel) [Internet]. Cancers (Basel); 2021 [cited 2023 Nov 29];13:1–15. Available from: https://pubmed.ncbi.nlm.nih.gov/33807785/
26. Oren Y, Tsabar M, Cuoco MS, Amir-Zilberstein L, Cabanos HF, Hütter JC, et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature 2021 596:7873 [Internet]. Nature Publishing Group; 2021 [cited 2023 Nov 29];596:576–82. Available from: https://www.nature.com/articles/s41586-021-03796-6
27. Müller T, Kalxdorf M, Rémiazdal DN, Krijgsveld A. Automated sample preparation with SP3 for low-input clinical proteomics. Molecular System Biology. 2020;
28. Hughes CS, Moggridge S, Müller T, Sorensen PH, Morin GB, Krijgsveld J. Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nat Protoc. Springer US; 2019;14:68–85.
29. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nature Biotechnology 2008 26:12 [Internet]. Nature Publishing Group; 2008 [cited 2023 Dec 13];26:1367–72. Available from: https://www.nature.com/articles/nbt.1511
30. Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nature Methods 2016 13:9 [Internet]. Nature Publishing Group; 2016 [cited 2023 Dec 13];13:731–40. Available from: https://www.nature.com/articles/nmeth.3901
31. Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res [Internet]. Oxford University Press; 2022 [cited 2023 Dec 11];50:W216. Available from: /pmc/articles/PMC9252805/
32. Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res [Internet]. Nucleic Acids Res; 2023 [cited 2023 Dec 13];51:D638–46. Available from: https://pubmed.ncbi.nlm.nih.gov/36370105/
33. Matthiesen R, Trelle MB, Højrup P, Bunkenborg J, Jensen ON. VEMS 3.0: Algorithms and computational tools for tandem mass spectrometry based identification of post-translational modifications in proteins. J Proteome Res [Internet]. American Chemical Society ; 2005 [cited 2023 Nov 29];4:2338–47. Available from: https://pubs.acs.org/doi/full/10.1021/pr050264q
34. Histone western blot protocol | abcam [Internet]. [cited 2023 Nov 29]. Available from: https://www.abcam.com/en-pt/technical-resources/protocols/histone-western-blot
35. Wiecek AJ, Cutty SJ, Kornai D, Parreno-Centeno M, Gourmet LE, Tagliazucchi GM, et al. Genomic hallmarks and therapeutic implications of G0 cell cycle arrest in cancer. Genome Biol [Internet]. Genome Biol; 2023 [cited 2023 Nov 29];24. Available from: https://pubmed.ncbi.nlm.nih.gov/37221612/
36. Eid A, Eshein A, Li Y, Virk R, Van Derway D, Zhang D, et al. Characterizing chromatin packing scaling in whole nuclei using interferometric microscopy. Opt Lett [Internet]. NIH Public Access; 2020 [cited 2024 Jan 30];45:4810. Available from: /pmc/articles/PMC7951997/
37. Gladstein S, Almassalha LM, Cherkezyan L, Chandler JE, Eshein A, Eid A, et al. Multimodal interference-based imaging of nanoscale structure and macromolecular motion uncovers UV induced cellular paroxysm. Nat Commun [Internet]. Nat Commun; 2019 [cited 2024 Jan 30];10. Available from: https://pubmed.ncbi.nlm.nih.gov/30971691/
38. Li Y, Eshein A, Virk RKA, Eid A, Wu W, Frederick J, et al. Nanoscale Chromatin Imaging and Analysis (nano-ChIA) platform bridges 4-D chromatin organization with molecular function. bioRxiv [Internet]. Cold Spring Harbor Laboratory; 2020 [cited 2024 Jan 30];2020.01.26.920363. Available from: https://www.biorxiv.org/content/10.1101/2020.01.26.920363v2
39. Virk RKA, Wu W, Almassalha LM, Bauer GM, Li Y, VanDerway D, et al. Disordered chromatin packing regulates phenotypic plasticity. Sci Adv [Internet]. Sci Adv; 2020 [cited 2024 Jan 30];6. Available from: https://pubmed.ncbi.nlm.nih.gov/31934628/
40. Durand NC, Shamim MS, Machol I, Rao SSP, Huntley MH, Lander ES, et al. Juicer provides a one-click system for analyzing loop-resolution Hi-C experiments. Cell Syst [Internet]. NIH Public Access; 2016 [cited 2024 Jan 25];3:95. Available from: /pmc/articles/PMC5846465/
41. Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C, et al. TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers. Cell. Cell Press; 2012;148:639–50.
42. Mathison AJ, Kerketta R, de Assuncao TM, Leverence E, Zeighami A, Urrutia G, et al. KrasG12D induces changes in chromatin territories that differentially impact early nuclear reprogramming in pancreatic cells. Genome Biol [Internet]. BioMed Central Ltd; 2021 [cited 2024 Jan 30];22:1–29. Available from: https://genomebiology.biomedcentral.com/articles/10.1186/s13059-021-02498-6
43. Li Y, Agrawal V, Virk RKA, Roth E, Li WS, Eshein A, et al. Analysis of three-dimensional chromatin packing domains by chromatin scanning transmission electron microscopy (ChromSTEM). Scientific Reports 2022 12:1 [Internet]. Nature Publishing Group; 2022 [cited 2024 Jan 30];12:1–15. Available from: https://www.nature.com/articles/s41598-022-16028-2
44. Ciabrelli F, Cavalli G. Chromatin-Driven Behavior of Topologically Associating Domains. J Mol Biol. Academic Press; 2015;427:608–25.
45. Rao SSP, Huntley MH, Durand NC, Stamenova EK, Bochkov ID, Robinson JT, et al. A three-dimensional map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell [Internet]. NIH Public Access; 2014 [cited 2024 Jan 30];159:1665. Available from: /pmc/articles/PMC5635824/
46. Lieberman-Aiden E, Van Berkum NL, Williams L, Imakaev M, Ragoczy T, Telling A, et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science (1979) [Internet]. American Association for the Advancement of Science; 2009 [cited 2024 Jan 30];326:289–93. Available from: https://www.science.org/doi/10.1126/science.1181369
47. Ghavi-Helm Y, Jankowski A, Meiers S, Viales RR, Korbel JO, Furlong EEM. Highly rearranged chromosomes reveal uncoupling between genome topology and gene expression. Nat Genet. Nature Publishing Group; 2019;51:1272–82.
48. Xiao J, Hafner A, Boettiger AN. How subtle changes in 3d structure can create large changes in transcription. Elife. eLife Sciences Publications Ltd; 2021;10.
49. Biswas A, Sahoo S, Riedlinger GM, Ghodoussipour S, Jolly MK, De S. Transcriptional state dynamics lead to heterogeneity and adaptive tumor evolution in urothelial bladder carcinoma. Communications Biology 2023 6:1 [Internet]. Nature Publishing Group; 2023 [cited 2024 Jan 25];6:1–18. Available from: https://www.nature.com/articles/s42003-023-05668-3
50. Sabnis AJ, Bivona TG. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends Mol Med [Internet]. Trends Mol Med; 2019 [cited 2023 Nov 29];25:185–97. Available from: https://pubmed.ncbi.nlm.nih.gov/30686761/
51. Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors . New England Journal of Medicine [Internet]. Massachusetts Medical Society; 2020 [cited 2023 Nov 29];383:1207–17. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1917239
52. Mao Z, Xiao H, Shen P, Yang Y, Xue J, Yang Y, et al. KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Cell Discovery 2022 8:1 [Internet]. Nature Publishing Group; 2022 [cited 2023 Nov 29];8:1–14. Available from: https://www.nature.com/articles/s41421-021-00368-w
53. Xue JY, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, et al. Rapid non-uniform adaptation to conformation-specific KRASG12C inhibition. Nature [Internet]. NIH Public Access; 2020 [cited 2023 Nov 29];577:421. Available from: /pmc/articles/PMC7308074/
54. Stubbs CK, Biancucci M, Vidimar V, Satchell KJF. RAS specific protease induces irreversible growth arrest via p27 in several KRAS mutant colorectal cancer cell lines. Sci Rep [Internet]. Nature Publishing Group; 2021 [cited 2023 Nov 29];11:17925. Available from: /pmc/articles/PMC8429734/
55. Cabanos HF, Hata AN. Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer. Cancers 2021, Vol 13, Page 2666 [Internet]. Multidisciplinary Digital Publishing Institute; 2021 [cited 2023 Nov 29];13:2666. Available from: https://www.mdpi.com/2072-6694/13/11/2666/htm
56. Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nature Reviews Drug Discovery 2019 19:1 [Internet]. Nature Publishing Group; 2019 [cited 2023 Nov 29];19:39–56. Available from: https://www.nature.com/articles/s41573-019-0044-1
57. Yang C, Tian C, Hoffman TE, Jacobsen NK, Spencer SL. Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signaling. Nature Communications 2021 12:1 [Internet]. Nature Publishing Group; 2021 [cited 2023 Nov 29];12:1–14. Available from: https://www.nature.com/articles/s41467-021-21549-x
58. Sharma S V., Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations. Cell [Internet]. Elsevier B.V.; 2010 [cited 2023 Dec 6];141:69–80. Available from: http://www.cell.com/article/S0092867410001807/fulltext
59. Rehman SK, Haynes J, Collignon E, Brown KR, Wang Y, Nixon AML, et al. Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy. Cell. Cell Press; 2021;184:226-242.e21.
60. Almassalha LM, Bauer GM, Wu W, Cherkezyan L, Zhang D, Kendra A, et al. Macrogenomic engineering via modulation of the scaling of chromatin packing density. Nature Biomedical Engineering 2017 1:11 [Internet]. Nature Publishing Group; 2017 [cited 2024 Jan 30];1:902–13. Available from: https://www.nature.com/articles/s41551-017-0153-2